Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Here not hear!
Interesting to hear from the geniuses hear who turned it down at 10p and now think it’s worth 20p just about ??
Some lacking in very basic account principles and valuation methodologies
Even if it is not a full blown court case it is a public dispute. If it were a simple disagreement it seems unlikely it would go into an RNS and legal advice be sought.
Until we know the exact cause of the dispute the cash pile is questionable as folks will be thinking that it could a) be sucked up by legal costs b) lose some reserves to resolve a dispute.
Margins are still a decent level but they will keep dropping, especially as bigger companies flood the market.
Given all current headwinds and potential of NCYT over the next few years is it still a good buy at these prices? I feel like it’s a no. If someone comes up with a good LFT that will cook NCYT’s goose well and truly.
One thing that is rarely mentioned is the fact that margins for covid testing will fall over the next 12 months and beyond. There is no way current margins will be maintained as the market matures and new entrants arrive. Last year NCYT had a first mover advantage which was reflected in pricing, as this becomes more commoditised unique IP will be ever more important to drive value. Matching the pack won’t do it so likely R&D costs will increase to stay ahead of / level with the pack.
I also wanted to mention that a big part of the valuation / optimism for NCYT was that the government contract / placement of machines made cross selling other tests a real possibility - ie Multiplex and beyond. With the legal case where does this leave that? The legal case also shows that all conventional soft means (ie negotiation) have failed. NCYT may well win the legal case but the message this will send to prospective clients is not positive, the largest contract you had ended in legal action.
When you consider these risks is this really that attractive a buy based on potential upsides? There are many cheaper stocks on AIM with more palatable risk profiles that could deliver similar results to NCYT.
I don’t see many buyers at this level. Yes they have cash but share prices are forward looking. £2 then you may tempt a few.
I’ve recently taken a position hear at just under 150. Intrigued by the technology as well as Amarti taking a position. They seem to be advocates of patient money and relatively unique in targeting early stage illiquid aim stocks in biosciences. I like Paul Jourdan, he seems like a sensible fellow and a good stick picker. Fingers crossed for green pastures ahead.
It will be done via a SPAC - not an IPO
Could be a US investor, you’d think if it was a UK based investor they’d have taken out a SB as it doesn’t attract CGT. a CFD only avoids SDRT.
Good news regardless
PS - I agree 4D is a great share :)
Good news on that one today....
Your basing your opinion on a capital rise on? You assume it will be at a discount to the SP - I highly doubt that.
Good luck with with your entry.......
This is oversold, someone has been exiting a position for a fortnight which hasn’t helped.
Citadel down to 0.44% from 0.61%
Positive.
Looking for an entry I take it?